Linden Thomas Advisory Services’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.63M Sell
18,528
-148
-0.8% -$23.8K 0.21% 151
2026
Q2
$3.15M Buy
18,676
+11,215
+150% +$1.66M 0.25% 115
2026
Q1
$983K Buy
7,461
+650
+10% +$86.2K 0.09% 319
2025
Q4
$966K Sell
6,811
-34
-0.5% -$4.93K 0.1% 304
2025
Q3
$961K Buy
6,845
+146
+2% +$19.8K 0.1% 304
2025
Q2
$842K Buy
6,699
+96
+1% +$11K 0.09% 322
2025
Q1
$730K Buy
6,603
+253
+4% +$32K 0.09% 327
2024
Q4
$867K Buy
6,350
+289
+5% +$35.7K 0.11% 307
2024
Q3
$698K Buy
6,061
+265
+5% +$36.3K 0.1% 329
2024
Q2
$798K Sell
5,796
-972
-14% -$133K 0.12% 299
2024
Q1
$933K Buy
6,768
+312
+5% +$42.6K 0.15% 274
2023
Q4
$851K Buy
6,456
+225
+4% +$25.9K 0.16% 261
2023
Q3
$701K Sell
6,231
-9,302
-60% -$980K 0.16% 275
2023
Q2
$1.46M Buy
15,533
+138
+0.9% +$13.5K 0.33% 106
2023
Q1
$1.56M Buy
15,395
+371
+2% +$38.6K 0.39% 88
2022
Q4
$1.79M Buy
+15,024
New +$1.76M 0.51% 48

Other funds holding NBIX

Linden Thomas Advisory Services's NBIX Position: Q3 2026 in Review

Linden Thomas Advisory Services reduced its Neurocrine Biosciences (NBIX) stake by 0.79% in Q3 2026, selling an estimated $23.8K and leaving 18,528 shares worth $2.63M. The position accounts for 0.21% of the portfolio, ranked #151.

Linden Thomas Advisory Services first reported a position in NBIX in Q4 2022 and has held it in 16 quarters since. The position peaked at $3.15M in Q2 2026. 766 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Linden Thomas Advisory Services held 18,528 shares of Neurocrine Biosciences worth $2.63M as of Q3 2026.
  • Linden Thomas Advisory Services sold 148 Neurocrine Biosciences shares in Q3 2026, an estimated $23.8K.
  • Neurocrine Biosciences made up 0.21% of Linden Thomas Advisory Services's portfolio in Q3 2026, its #151 holding.
  • Linden Thomas Advisory Services first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 16 quarters since.
  • Linden Thomas Advisory Services's Neurocrine Biosciences position peaked at $3.15M in Q2 2026.
  • 766 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Linden Thomas Advisory Services's 13F filing for Q3 2026, filed 19 Oct 2026.